Overview

Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction

Status:
Completed
Trial end date:
2018-03-30
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine whether combination therapy with Tolterodine ER and Tamsulosin is more effective than monotherapy with tamsulosin alone in reducing stent symptoms. The second purpose is to determine if people have less stent discomfort if they take these medications starting 2 weeks before the stent is placed The investigators hope to show that the addition of Tolterodine ER to Tamsulosin will provide added benefits in reducing stent symptoms in patients who have had unilateral placement of a ureteral stent.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Wisconsin, Madison
Treatments:
Cholinergic Antagonists
Tamsulosin
Tolterodine Tartrate
Criteria
Inclusion Criteria:

- Patients with unilateral ureteral stent placement for urolithiasis

Exclusion Criteria:

1. Pre-existing lower urinary tract symptoms

2. Active urinary tract infection

3. Contraindication to anticholinergic medication

1. Prior hypersensitivity or allergy to tolterodine

2. Patients with severe hepatic impairment (Child-Pugh Class C)

3. Patients with uncontrolled close (narrow) angle glaucoma

4. Patients with urinary retention

4. Current anticholinergic use

5. Chronic pelvic pain syndromes (e.g. acute/chronic prostatitis, interstitial cystitis)

6. Women who are pregnant or nursing

7. Under 18 years of age

8. Prior hypersensitivity or allergy to tolterodine

9. Patients with severe hepatic impairment (Child-Pugh Class C)

10. Patients with uncontrolled close (narrow) angle glaucoma

11. Patients with urinary retention

12. Unable to provide informed consent